Epigenetic therapies in acute myeloid leukemia: where to from here?
- 28 November 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (22) , 1891-1901
Abstract
In a Perspective, Fennell et al review the current state of epigenetic therapies for acute myeloid leukemia, highlighting their proposed mechanisms of action, the role of the immune system in mediating their response, and the outlook for new agents and combined therapies to maximize their potential efficacy.Keywords
This publication has 98 references indexed in Scilit:
- Functional genomic landscape of acute myeloid leukaemiaNature, 2018
- Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic ModifiersCancer Discovery, 2017
- The cancer epigenome: Concepts, challenges, and therapeutic opportunitiesScience, 2017
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationCancer Cell, 2010
- Quantitative DNA methylation predicts survival in adult acute myeloid leukemiaBlood, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeNew England Journal of Medicine, 2009